CR20240163A - Formas cristalinas de derivados de quinazolina, preparación, composición y uso de estas - Google Patents

Formas cristalinas de derivados de quinazolina, preparación, composición y uso de estas

Info

Publication number
CR20240163A
CR20240163A CR20240163A CR20240163A CR20240163A CR 20240163 A CR20240163 A CR 20240163A CR 20240163 A CR20240163 A CR 20240163A CR 20240163 A CR20240163 A CR 20240163A CR 20240163 A CR20240163 A CR 20240163A
Authority
CR
Costa Rica
Prior art keywords
crystalline forms
preparation
composition
quinazoline derivatives
methoxyquinazolin
Prior art date
Application number
CR20240163A
Other languages
English (en)
Inventor
Zheng Wang
Ding Zhou
Ziqiang Cheng
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20240163A publication Critical patent/CR20240163A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/14—Adipic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/185—Saturated compounds having only one carboxyl group and containing keto groups
    • C07C59/225—Saturated compounds having only one carboxyl group and containing keto groups containing —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se divulgan formas cristalinas de (R)-N-(4-([1,2,4]triazolo[1,5-c]pirimidin-7-iloxi)- 3-metilfenil)-5-((3,3-difluoro-1-metilpiperidin-4-il)oxi)-6-metoxiquinazolin-4-amina, métodos para la preparación de estas, composiciones farmacéuticas que comprenden una o más de las formas cristalinas como un ingrediente activo, y uso de las formas cristalinas en el tratamiento de enfermedades hiperproliferativas
CR20240163A 2021-10-20 2022-10-19 Formas cristalinas de derivados de quinazolina, preparación, composición y uso de estas CR20240163A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2021125016 2021-10-20
PCT/CN2022/126169 WO2023066296A1 (en) 2021-10-20 2022-10-19 Crystalline forms of quinazoline derivatives, preparation, composition and use thereof

Publications (1)

Publication Number Publication Date
CR20240163A true CR20240163A (es) 2024-06-12

Family

ID=86057927

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20240163A CR20240163A (es) 2021-10-20 2022-10-19 Formas cristalinas de derivados de quinazolina, preparación, composición y uso de estas

Country Status (25)

Country Link
US (1) US20240417403A1 (es)
EP (2) EP4399207B1 (es)
JP (2) JP2024539212A (es)
KR (1) KR20240090181A (es)
CN (4) CN120623183A (es)
AU (1) AU2022371540B2 (es)
CA (1) CA3232101A1 (es)
CL (1) CL2024001231A1 (es)
CO (1) CO2024004745A2 (es)
CR (1) CR20240163A (es)
DK (1) DK4399207T3 (es)
ES (1) ES3059167T3 (es)
FI (1) FI4399207T3 (es)
HR (1) HRP20260049T1 (es)
IL (1) IL312004A (es)
LT (1) LT4399207T (es)
MA (1) MA66471B1 (es)
MX (1) MX2024004738A (es)
PE (1) PE20242106A1 (es)
PL (1) PL4399207T3 (es)
PT (1) PT4399207T (es)
RS (1) RS67641B1 (es)
SI (1) SI4399207T1 (es)
SM (1) SMT202600023T1 (es)
WO (1) WO2023066296A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
TW202602446A (zh) 2024-03-19 2026-01-16 瑞士商豪夫邁 羅氏有限公司 Ｅｒｂｂ２抑制劑的藥物製劑

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
DE602006021645D1 (de) * 2005-11-15 2011-06-09 Array Biopharma Inc Verfahren und Zwischenverbindungen zur Herstellung von N4-Phenyl-Quinazolin-4-Amin Derivaten
CN115057861A (zh) * 2016-03-01 2022-09-16 上海医药集团股份有限公司 一种含氮杂环化合物、制备方法、中间体、组合物和应用
EP3516071B1 (en) * 2016-09-22 2021-02-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of lung cancer
TWI811358B (zh) * 2018-05-08 2023-08-11 大陸商迪哲（江蘇）醫藥股份有限公司 ＥｒｂＢ受體抑制劑
HRP20240293T1 (hr) * 2018-09-18 2024-05-24 F. Hoffmann - La Roche Ag Derivati kinazolina kao protutumorska sredstva

Also Published As

Publication number Publication date
CN119317625A (zh) 2025-01-14
FI4399207T3 (fi) 2026-01-28
EP4717689A3 (en) 2026-06-17
JP2026027273A (ja) 2026-02-18
PL4399207T3 (pl) 2026-03-23
CN120623183A (zh) 2025-09-12
IL312004A (en) 2024-06-01
CN120309621A (zh) 2025-07-15
LT4399207T (lt) 2026-02-10
WO2023066296A1 (en) 2023-04-27
AU2022371540B2 (en) 2026-08-13
CN120309620A (zh) 2025-07-15
EP4399207A1 (en) 2024-07-17
US20240417403A1 (en) 2024-12-19
AU2022371540A1 (en) 2024-03-21
PE20242106A1 (es) 2024-10-28
MX2024004738A (es) 2024-05-14
EP4717689A2 (en) 2026-04-01
RS67641B1 (sr) 2026-02-27
CO2024004745A2 (es) 2024-04-29
SI4399207T1 (sl) 2026-04-30
PT4399207T (pt) 2026-01-16
KR20240090181A (ko) 2024-06-21
ES3059167T3 (en) 2026-03-19
SMT202600023T1 (it) 2026-03-09
MA66471B1 (fr) 2026-02-27
HRP20260049T1 (hr) 2026-02-27
JP2024539212A (ja) 2024-10-28
CL2024001231A1 (es) 2024-08-09
EP4399207B1 (en) 2025-11-26
EP4399207A4 (en) 2025-03-19
DK4399207T3 (da) 2026-02-02
CA3232101A1 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
PH12022552745A1 (en) [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS
JOP20220267A1 (ar) مركبات أمينو ثيازول تحمل بدائل بصفتها مثبطات لـثنائي أسيل غليسرول كيناز زيتا لتنشيط المناعة
BRPI0513811A (pt) imidazo [4,5-d] pirimidinas, seus usos e processos de preparação
MX2024000234A (es) Inhibidores del inflamasoma nlrp3.
NO20092529L (no) Substituerte 2,3-dihydroimidazo[1,2-c]kinazolinderivater som er anvendbare for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese
DOP2000000114A (es) Oxazolidinonas substituidas y su uso
WO2007007919A3 (en) Heterocyclic janus kinase 3 inhibitors
NO20060113L (no) Pyrrolo(3,4-c)pyrazolderivater aktive som kinase inhibitorer
NO20065638L (no) Formuleringer med kontrollert frigivelse inneholdende vardenafil
BRPI0113042B8 (pt) composto da fórmula ou um seu solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica, método para o tratamento de um indivíduo humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para preparar um composto ou um seu solvato
MX2024004738A (es) Formas cristalinas de derivados de quinazolina, preparacion, composicion y uso de estas.
BRPI0507653A (pt) derivados de imidazopiridina e imidazopiridina formulação farmacêutica compreendendo os mesmos e uso
JP2005502643A (ja) 白血病処置のための単独またはｓｔｉ５７１と組み合せたｃ−ｓｒｃインヒビターの使用
BR0213522B8 (pt) compostos derivados de hidroxipirimidinona, composição farmacêutica, e, uso de um composto
IL182893A0 (en) PYRAZOLO-[1,5-a] PYRIMIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
BRPI0412526A (pt) composto, uso de um composto, composição farmacêutica, formulação em aerossol farmacêutica, e, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica
WO2021074620A9 (en) [1,4]oxazepino[2,3-c]quinolinone derivatives as bcl6 inhibitors
MX2021016055A (es) Formulaciones y métodos de parasiticidas de isoxazolina para el tratamiento de la blefaritis.
MX2020006309A (es) Fórmulaciones de parasiticida de isoxazolina y métodos para el tratamiento de la blefaritis.
PH12019500597B1 (en) CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE
TW200633978A (en) 2,3,4,9-tetrahydro-1H-carbazole derivatives as crth2 receptor antagonists
ZA202309969B (en) Laquinimod formulation for ocular use
MX2022004878A (es) Derivados de n-(heteroaril)quinazolin-2-amina a manera de inhibidores de lrrk2, composiciones farmaceuticas y usos de los mismos.
BRPI0409818A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
BRPI0409878A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos